Ozempic's Patent Just Expired in India —
Here's What Cheap Semaglutide Actually Looks Like

Novo Nordisk's Ozempic patent didn't have one expiration date — it had several, in several countries, and that confusion is exactly why so many people still don't know where things stand. The semaglutide patent expiry that actually mattered arrived in India on 20 March 2026, and within 48 hours of that patent expiration date, more than 15 domestic drugmakers had launched generic semaglutide in India at a fraction of the branded price. A tablet strip of paracetamol costs less than a cup of chai. A month of injectable semaglutide, until recently, cost more than what a lot of Indian households spend on food in that same month. For a molecule treating a condition affecting over 100 million people in India alone, that gap between "this drug works" and "this drug is affordable" defined the last three years of this story. In March 2026, the gap closed — fast, and by court order rather than by Novo Nordisk's choice.

What semaglutide is, and why one drug ended up with two patents

Semaglutide is a GLP-1 receptor agonist — a lab-engineered analogue of a natural gut hormone that helps regulate blood sugar and appetite. The native hormone breaks down in the body within one to two minutes, which makes it useless as a once-weekly injection. Semaglutide gets around this through a handful of deliberate chemical modifications: one amino acid swap that resists the enzyme that would normally destroy it, and a fatty-acid side chain that lets it bind to albumin in the blood, dramatically slowing how fast the kidneys clear it out. The result is a molecule close enough to the original hormone to activate the same receptors, but stable enough to dose once a week instead of continuously.

That engineering is also why one drug ended up protected by more than one patent in India. In 2004, Novo Nordisk filed a broad "genus" patent — IN'964 — covering a wide family of GLP-1 analogues, semaglutide included, without naming it specifically. Three years later, in 2007, the company filed a second, narrower "species" patent — IN'697 — this time covering semaglutide's actual formulation and delivery in detail. The genus patent is the one that expired quietly in September 2024. The species patent is the one everyone was actually watching, because it was the one still standing between Indian manufacturers and a generic launch.

The court case that decided this early — Novo Nordisk vs Dr Reddy's

Dr Reddy's didn't wait for IN'697 to expire on its own. From early 2025, the company began manufacturing semaglutide API in India, betting that the second patent wouldn't survive a legal challenge if it came to one. Novo Nordisk responded in May 2025 with an infringement suit in Delhi High Court against Dr Reddy's and its manufacturing partner, OneSource Specialty Pharma, seeking to block them from making or exporting the drug at all.

In December 2025, a single judge declined to grant Novo Nordisk's injunction. The reasoning was specific: Dr Reddy's had raised a credible argument that IN'697 was invalid, because the compound it claimed had, in the court's assessment, already been disclosed by Novo Nordisk's own earlier genus patent from 2004. In legal terms, a "person skilled in the art" could arguably have arrived at semaglutide from what the 2004 patent already revealed — which would make the 2007 patent obvious, not new. Dr Reddy's was allowed to keep manufacturing and exporting to countries where the patent didn't apply, but it gave an undertaking not to sell in India until IN'697 formally expired.

Novo Nordisk appealed. On 9 March 2026 — eleven days before the patent's scheduled expiry — a Delhi High Court division bench dismissed that appeal. The bench went further than the single judge, describing the pattern as "double patenting" and effectively as evergreening: filing a second, narrower patent over ground the company had already claimed in the first, to keep the clock running longer than a single filing would have allowed.

What launched, and what it actually costs now

The moment IN'697 lapsed, the floodgates opened. Dr Reddy's launched first, under the brand name Obeda — a pre-filled disposable injector pen, and the first product to receive DCGI clearance for generic semaglutide in India. The company had said publicly it was aiming to price it up to 60% below the branded product; the actual retail figure that reached patients came in even lower, around ₹4,200 a month, close to a 90% discount against what branded Ozempic and Wegovy had been selling for.

Dr Reddy's wasn't alone for long. Within 48 hours, more than 15 companies had products in the market, and the list kept growing:

• Zydus Lifesciences — Semaglyn, Mashema, Alterme
• Sun Pharma — Sematrinity, Noveltreat, both backed by domestic Phase III trials showing non-inferiority to Ozempic
• Alkem Laboratories — Semasize, Obesema, Hepaglide
• Natco Pharma — Semanat, Semafull, priced from as low as ₹1,290 a month
• Glenmark Pharmaceuticals — Glipiq
• Eris Lifesciences — Sundae
• Torrent Pharmaceuticals — Sembolic, Semalix
• Mankind Pharma — Samakind

More than 50 branded generics are expected in total, and the names will keep multiplying — this is the same "slum of generics" naming pattern you'll recognise from any off-patent molecule in India, where any company with manufacturing and DCGI approval is free to launch under whatever brand name it chooses. Branded injectable semaglutide had been running between roughly ₹17,000 and ₹26,000 a month through 2025. By the time generics were on shelves, that had collapsed to a range of roughly ₹1,290 to ₹4,200 — a price cut of 60 to 90% depending on the brand.

Novo Nordisk didn't sit still either. Ahead of the expiry, the company cut Wegovy's Indian price by 37% and struck a distribution partnership with Emcure Pharma to widen its own reach before the generic wave hit. It was a defensive move that softened the fall slightly, but it didn't come close to matching what the generics undercut it by.

When does the rest of the world catch up?

This is the part that gets lost in most coverage: semaglutide's patent situation is not one global date. It's a jurisdiction-by-jurisdiction patchwork, and India moved first for reasons specific to how Indian patent law treats genus-versus-species filings — not because India's patent term is shorter across the board.

China is its own separate saga. A 2022 Chinese court ruling initially invalidated Novo Nordisk's semaglutide patent there, citing insufficient experimental data disclosure. China's Supreme People's Court later overturned that invalidation, and Novo Nordisk is now arguing that a data-exclusivity provision in the China–Switzerland Free Trade Agreement protects its Swiss subsidiary's regulatory data until April 2027 — regardless of what happens to the underlying patent. Chinese domestic biotech firms aren't waiting for that to resolve. Hangzhou Jiuyuan Genetic Biopharmaceutical, a subsidiary of Huadong Medicine, filed China's first semaglutide biosimilar application back in April 2024 and has since run Phase III trials comparing its candidate directly against both Ozempic and Wegovy.

In the US, the picture is more settled but much slower. Novo Nordisk's core compound patent, after patent term extension for regulatory review delays, runs until 5 December 2031. Layered formulation patents on the injector pen and method-of-use patents on dosing protocols push realistic generic entry into 2032 and 2033, and the oral Rybelsus tablet has its own separate formulation patent protecting it into 2032. At least 13 companies have already told the FDA they're interested in filing for generic approval — the interest is there, the timeline just isn't close yet.

Compounded semaglutide is not the same thing as generic semaglutide

This distinction gets muddled constantly, and it's worth being precise about it. Compounded semaglutide — the version some US pharmacies have been legally preparing — exists under a specific FDA exemption tied to drug shortages, not to any patent expiring. It has nothing to do with the timeline discussed above. When a branded drug is officially listed as being in shortage, compounding pharmacies are permitted to prepare their own versions to meet demand the manufacturer can't. That exemption can be withdrawn the moment the shortage is declared resolved, regardless of what's happening with Novo Nordisk's patents.

A true generic is a different thing entirely: a product approved by a national regulator — the DCGI in India, the FDA in the US — to the same manufacturing and quality standard as the original, and legally sold only once the relevant patent has actually expired or been successfully challenged. The India launches described above are generics in this proper sense. Anything sold as "compounded semaglutide" is not, and confusing the two is one of the most common errors in coverage of this topic.

Why India moved first — and why that's not an accident

India getting there before the US or Europe isn't a coincidence of timing. It's the direct result of the genus-species patent structure Novo Nordisk itself created when it filed two overlapping patents nine years apart. Filing a narrower species patent after a broad genus patent is a completely standard part of pharmaceutical patent strategy — the same pattern of layered patents that Pfizer used to try to extend Lipitor's commercial life past its core patent expiry. What made this case different is that Indian courts were willing to scrutinise how much genuine novelty separated the two filings, and found the gap wasn't wide enough.

It also helped that India had the manufacturing base ready to move the instant the legal question was settled. Dr Reddy's had already been producing semaglutide API for export since early 2025, anticipating this outcome. That's a familiar pattern for anyone who has followed how Indian generic manufacturers built their global reputation — the capability to scale a molecule to hundreds of millions of doses the moment the legal door opens is not something companies build overnight. It's built years in advance, on a bet.

What this means if you're in pharma

If you're heading into regulatory affairs, patent law, or a generics-side commercial role, this case is worth understanding in real detail rather than at headline level — it's a live, recent example of genus-versus-species patent litigation actually working in a generic challenger's favour, decided on obviousness grounds rather than the more commonly cited Section 3(d). That distinction is the kind of thing that separates someone who followed the story from someone who can actually explain the legal mechanics of it in an interview.

It's also a useful companion piece to how Pfizer defended Lipitor's patent cliff a decade earlier — the commercial playbook for facing a cliff (price cuts, distribution deals, authorised generics) looks remarkably similar whether the molecule is a statin or a GLP-1 agonist. What differs each time is the legal terrain a challenger has to clear to get there, and that terrain is exactly what determines which country gets cheap access first.

Quick answers

Has Ozempic's patent actually expired in India?

Yes. Novo Nordisk's Indian formulation patent on semaglutide, IN'697, expired on 20 March 2026. Within 48 hours, more than 15 Indian drugmakers had launched generic semaglutide, with over 50 branded versions expected to follow. The underlying genus patent covering the broader class of GLP-1 analogues had already expired in September 2024.

Why did Dr Reddy's win the Delhi High Court case against Novo Nordisk?

The court found that Novo Nordisk's second, narrower patent on semaglutide was likely invalid because the compound was already disclosed in the company's own earlier, broader patent filed in 2004. A single judge denied Novo Nordisk's injunction request in December 2025, and a Delhi High Court division bench dismissed Novo Nordisk's appeal in March 2026, days before the patent's scheduled expiry.

How much does generic semaglutide cost in India now?

Branded injectable semaglutide was running between roughly ₹17,000 and ₹26,000 a month by 2025. Generic versions launched between roughly ₹1,290 and ₹4,200 a month, with some brands undercutting the branded price by close to 90 percent.

Is compounded semaglutide the same as generic semaglutide?

No. Compounded semaglutide is prepared by pharmacies under a drug-shortage exemption and is not an approved generic version of the drug. It exists independently of patent status and is not tied to any patent expiring. A true generic is a DCGI- or FDA-approved product manufactured to the same regulatory standard as the original.

When will Ozempic go generic in the US?

Novo Nordisk's core US compound patent, extended under patent term extension provisions, runs until December 2031. Formulation and method-of-use patents on the injectable pen push realistic generic entry into 2032 to 2033, and the oral Rybelsus formulation is separately protected into 2032.

If this was useful, the next piece worth reading is on Lipitor's patent cliff — the closest historical parallel, and a look at what happens to a company's commercial strategy in the years before and after a blockbuster molecule loses exclusivity.